About AbbVie (NYSE:ABBV)
AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions. It offers products in various categories, including HUMIRA (adalimumab), Oncology products, Virology Products, Additional Virology products, Metabolics/Hormones products, Endocrinology products and other products, which include Duopa and Duodopa (carbidopa and levodopa), Anesthesia products and ZINBRYTA (daclizumab).
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Specialty & Advanced Pharmaceuticals
- Sub-Industry: Pharmaceuticals
- Symbol: NYSE:ABBV
- CUSIP: 00287Y10
- Web: www.abbvie.com
- Market Cap: $153.19253 billion
- Outstanding Shares: 1,594,094,000
- 50 Day Moving Avg: $88.06
- 200 Day Moving Avg: $73.89
- 52 Week Range: $55.06 - $98.26
Sales & Book Value:
- Trailing P/E Ratio: 23.64
- Foreward P/E Ratio: 14.54
- P/E Growth: 1.24
- Annual Revenue: $26.71 billion
- Price / Sales: 5.74
- Book Value: $3.77 per share
- Price / Book: 25.49
- Annual Dividend: $2.56
- Dividend Yield: 2.7%
- EBITDA: $11.57 billion
- Net Margins: 24.77%
- Return on Equity: 150.27%
- Return on Assets: 12.52%
- Debt-to-Equity Ratio: 5.63%
- Current Ratio: 1.38%
- Quick Ratio: 1.25%
- Average Volume: 6.48 million shs.
- Beta: 1.51
- Short Ratio: 5.37
Frequently Asked Questions for AbbVie (NYSE:ABBV)
What is AbbVie's stock symbol?
AbbVie trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABBV."
How often does AbbVie pay dividends? What is the dividend yield for AbbVie?
AbbVie declared a quarterly dividend on Friday, September 8th. Stockholders of record on Friday, October 13th will be paid a dividend of $0.64 per share on Wednesday, November 15th. This represents a $2.56 dividend on an annualized basis and a dividend yield of 2.66%. The ex-dividend date of this dividend is Thursday, October 12th. View AbbVie's Dividend History.
How will AbbVie's stock buyback program work?
AbbVie declared that its board has initiated a stock repurchase program on Sunday, April 9th 2017, which allows the company to repurchase $5,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization allows the company to repurchase up to 5% of its stock through open market purchases. Stock repurchase programs are generally an indication that the company's board of directors believes its stock is undervalued.
How were AbbVie's earnings last quarter?
AbbVie Inc. (NYSE:ABBV) released its earnings results on Friday, July, 28th. The company reported $1.42 earnings per share for the quarter, topping the consensus estimate of $1.40 by $0.02. The company earned $6.94 billion during the quarter, compared to analyst estimates of $6.93 billion. AbbVie had a return on equity of 150.27% and a net margin of 24.77%. The company's quarterly revenue was up 7.6% on a year-over-year basis. During the same quarter last year, the business posted $1.26 EPS. View AbbVie's Earnings History.
When will AbbVie make its next earnings announcement?
What guidance has AbbVie issued on next quarter's earnings?
AbbVie updated its FY17 earnings guidance on Friday, July, 28th. The company provided earnings per share guidance of $5.44-5.54 for the period, compared to the Thomson Reuters consensus EPS estimate of $5.53.
Where is AbbVie's stock going? Where will AbbVie's stock price be in 2017?
16 equities research analysts have issued 12 month target prices for AbbVie's stock. Their forecasts range from $60.00 to $115.00. On average, they expect AbbVie's share price to reach $93.33 in the next twelve months. View Analyst Ratings for AbbVie.
What are analysts saying about AbbVie stock?
Here are some recent quotes from research analysts about AbbVie stock:
- 1. According to Zacks Investment Research, "AbbVie’s key drug Humira has been performing well and should continue to do well. Moreover, Imbruvica has multibillion dollar potential and AbbVie is exploring the possibility of label expansion into solid tumors and autoimmune diseases. Meanwhile, AbbVie has promising pipeline with several pivotal data readouts and regulatory milestones due in the second half. Maviret, approved recently, has the potential to rejuvenate AbbVie’s struggling HCV franchise. AbbVie’s shares have outperformed the industry this year so far. However, though Humira is doing well, the company is concerned about the product’s long-term growth prospects, given the potential biosimilar competition. Viekira also faces intense pricing and competitive pressure in the HCV market. Estimates have gone up slightly ahead of the company’s Q3 earnings release. AbbVie has had a mixed record of earnings surprises in the recent quarters." (10/20/2017)
- 2. UBS AG analysts commented, "For other pipeline products, we already included appropriate risk-adj estimates and in some cases significant risk adj sales (Rova-T)," (9/25/2017)
- 3. Jefferies Group LLC analysts commented, "ABBV's IPR with CHRS will be heard this week, which looks challenging in light of the prior institution decision. However, the market already expects ABBV to lose and we do not see the '135 patent alone as critical to delaying biosimilars, indicating positive asymmetry in our view. We look at the key IPR arguments as well as the risk/ reward around the decision expected in May as we prepare to attend the hearing." (2/14/2017)
Who are some of AbbVie's key competitors?
Some companies that are related to AbbVie include ConvaTec Group PLC (CTEC), Advanced Accelerator Applications S.A. (AAAP), Mallinckrodt PLC (MNK), Indivior PLC (INDV), Supernus Pharmaceuticals (SUPN), Aimmune Therapeutics (AIMT), Repligen Corporation (RGEN), TherapeuticsMD (TXMD), TherapeuticsMD (TXMD), Eagle Pharmaceuticals (EGRX), Assembly Biosciences (ASMB), Rockwell Medical (RMTI), NOVAN INC (NOVN), CorMedix (CRMD), Check-Cap (CHEK), DARA Biosciences (DARA), Macrocure Ltd (MCUR) and Salix Pharmaceuticals (SLXP).
Who are AbbVie's key executives?
AbbVie's management team includes the folowing people:
- Richard A. Gonzalez, Chairman of the Board, Chief Executive Officer
- William J. Chase, Executive Vice President, Chief Financial Officer
- Michael Severino M.D., Executive Vice President - Research & Development, Chief Scientific Officer
- Laura J. Schumacher, Executive Vice President, External Affairs, General Counsel and Corporate Secretary
- Carlos Alban, Executive Vice President - Commercial Operations
- Henry O. Gosebruch, Executive Vice President, Chief Strategy Officer
- Timothy J. Richmond, Senior Vice President - Human Resources
- Azita Saleki-Gerhardt Ph.D., Senior Vice President - Operations
- Robert A. Michael, Vice President, Controller
- Robert J. Alpern M.D., Independent Director
Who owns AbbVie stock?
AbbVie's stock is owned by many different of institutional and retail investors. Top institutional shareholders include APG Asset Management N.V. (0.12%), PGGM Investments (0.09%), Robeco Institutional Asset Management B.V. (0.06%), State Treasurer State of Michigan (0.04%), Fisher Asset Management LLC (0.04%) and Assenagon Asset Management S.A. (0.04%). Company insiders that own AbbVie stock include Azita Saleki-Gerhardt, Carlos Alban, Edward J Rapp, Henry O Gosebruch, Laura J Schumacher, Richard A Gonzalez, Robert A Michael, Thomas A Hurwich, Timothy J Richmond and William J Chase. View Institutional Ownership Trends for AbbVie.
Who sold AbbVie stock? Who is selling AbbVie stock?
AbbVie's stock was sold by a variety of institutional investors in the last quarter, including State Treasurer State of Michigan, Sit Investment Associates Inc., Sabal Trust CO, Bridges Investment Counsel Inc., Meeder Asset Management Inc., LS Investment Advisors LLC, Verde Servicos Internacionais S.A. and Private Asset Management Inc.. Company insiders that have sold AbbVie stock in the last year include Azita Saleki-Gerhardt, Carlos Alban, Henry O Gosebruch, Laura J Schumacher, Richard A Gonzalez, Robert A Michael, Timothy J Richmond and William J Chase. View Insider Buying and Selling for AbbVie.
Who bought AbbVie stock? Who is buying AbbVie stock?
AbbVie's stock was purchased by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., APG Asset Management N.V., PGGM Investments, Barometer Capital Management Inc., Shell Asset Management Co., Ingalls & Snyder LLC, Glynn Capital Management LLC and Robeco Institutional Asset Management B.V.. View Insider Buying and Selling for AbbVie.
How do I buy AbbVie stock?
Shares of AbbVie can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is AbbVie's stock price today?
MarketBeat Community Rating for AbbVie (NYSE ABBV)MarketBeat's community ratings are surveys of what our community members think about AbbVie and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of AbbVie stock can currently be purchased for approximately $96.10.
Consensus Ratings for AbbVie (NYSE:ABBV) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||6 Hold Ratings, 10 Buy Ratings|
|Consensus Rating:||Buy (Score: 2.63)|
|Consensus Price Target: ||$93.33 (2.88% downside)|Consensus Price Target History for AbbVie (NYSE:ABBV)
Analysts' Ratings History for AbbVie (NYSE:ABBV)
(Data available from 10/22/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|10/16/2017||Jefferies Group LLC||Boost Price Target||Buy||$107.00 -> $115.00||N/A|
|10/13/2017||Barclays PLC||Boost Price Target||Equal Weight||$90.00||N/A|
|10/11/2017||Cowen and Company||Upgrade||Market Perform -> Outperform||$91.17 -> $105.00||N/A|
|10/2/2017||Leerink Swann||Upgrade||Market Perform -> Outperform||$89.00 -> $106.00||Medium|
|10/1/2017||Credit Suisse Group||Reiterated Rating||Neutral||$74.00 -> $94.00||Medium|
|9/30/2017||Evercore ISI||Reiterated Rating||Outperform||$95.00 -> $100.00||Medium|
|9/28/2017||BMO Capital Markets||Reiterated Rating||Hold||$66.00||Low|
|9/29/2017||Argus||Boost Price Target||Buy||$90.00 -> $110.00||Low|
|9/29/2017||Morgan Stanley||Boost Price Target||Equal Weight||$70.00 -> $95.00||Low|
|9/28/2017||Deutsche Bank AG||Boost Price Target||Hold||$88.00||Low|
|9/15/2017||Piper Jaffray Companies||Reiterated Rating||Buy||$100.00||High|
|9/13/2017||SunTrust Banks, Inc.||Reiterated Rating||Buy||$95.00||Low|
|9/8/2017||Goldman Sachs Group, Inc. (The)||Reiterated Rating||Buy||$85.00 -> $100.00||Low|
|6/22/2017||Societe Generale||Upgrade||Hold -> Buy||Low|
|12/8/2016||William Blair||Reiterated Rating||Outperform||$76.00||N/A|
|11/28/2016||Citigroup Inc.||Downgrade||Buy -> Neutral||$60.00||N/A|
|9/8/2016||J P Morgan Chase & Co||Downgrade||Overweight -> Neutral||$75.00 -> $73.00||N/A|
|9/1/2016||Raymond James Financial, Inc.||Initiated Coverage||Outperform||$82.00||N/A|
|12/18/2015||Atlantic Securities||Initiated Coverage||Neutral||$59.00||N/A|
Earnings History for AbbVie (NYSE:ABBV)Earnings History by Quarter for AbbVie (NYSE ABBV)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|7/28/2017||Q2 2017||$1.40||$1.42||$6.93 billion||$6.94 billion||View||N/A|
|4/27/2017||Q1 2017||$1.26||$1.28||$6.49 billion||$6.54 billion||View||N/A|
|1/27/2017||Q416||$1.20||$1.20||$6.92 billion||$6.78 billion||View||Listen|
|10/28/2016||Q316||$1.21||$1.21||$6.55 billion||$6.43 billion||View||Listen|
|7/29/2016||Q216||$1.20||$1.26||$6.20 billion||$6.43 billion||View||Listen|
|4/28/2016||Q116||$1.14||$1.15||$6.03 billion||$5.96 billion||View||Listen|
|1/29/2016||Q415||$1.12||$1.13||$6.41 billion||$6.36 billion||View||Listen|
|10/30/2015||Q315||$1.08||$1.13||$5.90 billion||$4.94 billion||View||Listen|
|7/24/2015||Q215||$1.06||$1.08||$5.60 billion||$5.48 billion||View||Listen|
|4/23/2015||Q115||$0.85||$0.94||$718.50 million||$5.04 billion||View||Listen|
|1/30/2015||Q414||$0.86||$0.89||$5.34 billion||$5.45 billion||View||Listen|
|10/31/2014||Q3||$0.77||$0.89||$4.82 million||$5.02 million||View||Listen|
|7/25/2014||Q214||$0.76||$0.82||$4.70 billion||$4.93 billion||View||Listen|
|4/25/2014||Q114||$0.68||$0.71||$4.33 billion||$4.56 billion||View||Listen|
|1/31/2014||Q413||$0.82||$0.82||$5.10 billion||$5.11 billion||View||Listen|
|10/25/2013||Q313||$0.78||$0.82||$4.52 billion||$4.66 billion||View||Listen|
|7/26/2013||Q2 2013||$0.79||$0.92||$4.54 billion||$4.69 billion||View||Listen|
|4/26/2013||Q1 2013||$0.67||$0.68||$4.17 billion||$4.33 billion||View||Listen|
Earnings Estimates for AbbVie (NYSE:ABBV)
Current Year EPS Consensus Estimate: $5.53 EPS
Next Year EPS Consensus Estimate: $6.61 EPS
Current Dividend Information for AbbVie (NYSE:ABBV)
|Dividend Growth:||12.50% (3 Year Average)|
|Payout Ratio:||62.90% (Trailing 12 Months of Earnings) |
46.29% (Based on This Year's Estimates)
38.73% (Based on Next Year's Estimates)
|Track Record:||44 Years of Consecutive Dividend Growth|
Dividend History by Quarter for AbbVie (NYSE ABBV)
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Insider Trading and Institutional Ownership History for AbbVie (NYSE:ABBV)
Insider Ownership Percentage: 0.23%Insider Trades by Quarter for AbbVie (NYSE:ABBV)
Institutional Ownership Percentage: 68.25%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|9/28/2017||Robert A Michael||VP||Sell||6,699||$88.00||$589,512.00|| |
|9/11/2017||Azita Saleki-Gerhardt||SVP||Sell||8,300||$85.02||$705,666.00|| |
|8/7/2017||Richard A Gonzalez||Chairman||Sell||193,131||$71.00||$13,712,301.00|| |
|8/4/2017||Richard A Gonzalez||Chairman||Sell||87,899||$71.02||$6,242,586.98|| |
|8/3/2017||Richard A Gonzalez||CEO||Sell||65,861||$71.00||$4,676,131.00|| |
|7/31/2017||Edward J Rapp||Director||Buy||4,000||$70.45||$281,800.00|| |
|7/31/2017||Henry O Gosebruch||Insider||Sell||18,000||$70.09||$1,261,620.00|| |
|6/14/2017||Carlos Alban||EVP||Sell||45,800||$70.00||$3,206,000.00|| |
|6/14/2017||Laura J Schumacher||Insider||Sell||79,800||$70.00||$5,586,000.00|| |
|5/19/2017||Richard A Gonzalez||Chairman||Sell||71,235||$65.49||$4,665,180.15|| |
|5/18/2017||William J Chase||CFO||Sell||38,300||$65.35||$2,502,905.00|| |
|5/4/2017||Carlos Alban||EVP||Sell||43,000||$67.00||$2,881,000.00|| |
|3/10/2017||Laura J Schumacher||Insider||Sell||40,000||$65.26||$2,610,400.00|| |
|3/10/2017||Robert A Michael||VP||Sell||5,132||$65.29||$335,068.28|| |
|3/10/2017||Timothy J Richmond||SVP||Sell||22,451||$65.29||$1,465,825.79|| |
|3/8/2017||Richard A Gonzalez||Chairman||Sell||72,016||$64.25||$4,627,028.00|| |
|12/2/2016||William J Chase||CFO||Sell||6,600||$59.19||$390,654.00|| |
|9/7/2016||Laura J Schumacher||Insider||Sell||50,000||$65.00||$3,250,000.00|| |
|6/24/2016||Laura J Schumacher||EVP||Sell||186,106||$60.03||$11,171,943.18|| |
|6/2/2016||Richard A Gonzalez||CEO||Sell||285,953||$63.82||$18,249,520.46|| |
|5/11/2016||Richard A Gonzalez||CEO||Sell||39,000||$63.80||$2,488,200.00|| |
|5/10/2016||Carlos Alban||EVP||Sell||47,438||$63.52||$3,013,261.76|| |
|5/10/2016||Thomas A Hurwich||VP||Sell||6,000||$63.59||$381,540.00|| |
|5/10/2016||Timothy J Richmond||SVP||Sell||21,583||$63.52||$1,370,952.16|| |
|3/8/2016||Laura J Schumacher||EVP||Sell||25,000||$56.09||$1,402,250.00|| |
|3/1/2016||Timothy J Richmond||SVP||Sell||12,866||$55.05||$708,273.30|| |
|4/28/2015||Richard A Gonzalez||CEO||Sell||102,964||$64.67||$6,658,681.88|| |
|3/2/2015||Laura J Schumacher||EVP||Sell||25,000||$60.30||$1,507,500.00|| |
|3/2/2015||Timothy J Richmond||SVP||Sell||14,388||$60.33||$868,028.04|| |
|12/22/2014||William J Chase||CFO||Sell||8,495||$68.00||$577,660.00|| |
|3/4/2014||Richard Gonzalez||CEO||Sell||4,799||$51.20||$245,708.80|| |
|3/3/2014||Azita Saleki-Gerhardt||SVP||Sell||2,443||$50.25||$122,760.75|| |
|3/3/2014||Carlos Alban||EVP||Sell||2,882||$50.09||$144,359.38|| |
|3/3/2014||William Chase||CFO||Sell||3,948||$50.22||$198,268.56|| |
|9/17/2013||Azita Saleki-Gerhardt||SVP||Sell||10,473||$45.84||$480,082.32|| |
|8/19/2013||Azita Saleki-Gerhardt||SVP||Sell||1,270||$43.01||$54,622.70|| |
|8/12/2013||Azita Saleki-Gerhardt||SVP||Sell||8,851||$44.91||$397,498.41|| |
|3/11/2013||Edward J Rapp||Director||Buy||2,500||$37.67||$94,175.00|| |
|2/4/2013||Frederick H Waddell||Director||Buy||2,000||$37.05||$74,100.00|| |
Headline Trends for AbbVie (NYSE:ABBV)
Latest Headlines for AbbVie (NYSE:ABBV)
Loading headlines, please wait.
AbbVie (ABBV) Chart for Sunday, October, 22, 2017